Pharmaceuticals Global Group of Eight (G8) Industry Guide 2017

Date: May 31, 2017
Pages: 195
Price:
US$ 1,495.00 US$ 1,270.75
Offer valid until September 1, 2017!
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P8F9B249648EN
Leaflet:

Download PDF Leaflet

Pharmaceuticals Global Group of Eight (G8) Industry Guide 2017

SUMMARY

The G8 Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

SYNOPSIS

Essential resource for top-line data and analysis covering the G8 pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.

KEY HIGHLIGHTS
  • The G8 countries contributed $605.5 billion in 2016 to the global pharmaceuticals industry, with a compound annual growth rate (CAGR) of 5.4% between 2012 and 2016. The G8 countries are expected to reach a value of $803.9 billion in 2021, with a CAGR of 5.8% over the 2016-21 period.
  • Among the G8 nations, the US is the leading country in the pharmaceuticals industry, with market revenues of $377.0 billion in 2016. This was followed by Japan and France, with a value of $70.0 and $35.6 billion, respectively.
  • The US is expected to lead the pharmaceuticals industry in the G8 nations with a value of $530.8 billion in 2016, followed by Japan and Germany with expected values of $72.0 and $42.1 billion, respectively.
SCOPE
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the G8 pharmaceuticals market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the G8 pharmaceuticals market
  • Leading company profiles reveal details of key pharmaceuticals market players’ G8 operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the G8 pharmaceuticals market with five year forecasts
  • Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country
REASONS TO BUY
  • What was the size of the G8 pharmaceuticals market by value in 2016?
  • What will be the size of the G8 pharmaceuticals market in 2021?
  • What factors are affecting the strength of competition in the G8 pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitors in the G8 pharmaceuticals market?
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
Group of Eight (G) Pharmaceuticals
Industry Outlook
Pharmaceuticals in Canada
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in France
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Germany
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Italy
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Japan
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in Russia
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in The United Kingdom
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Pharmaceuticals in The United States
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine

LIST OF TABLES

Table 1: G8 pharmaceuticals industry, revenue($bn), 2012-21
Table 2: G8 pharmaceuticals industry, revenue by country ($bn), 2012-16
Table 3: G8 pharmaceuticals industry forecast, revenue by country ($bn), 2016-21
Table 4: Canada pharmaceuticals market value: $ billion, 2012–16
Table 5: Canada pharmaceuticals market geography segmentation: $ billion, 2016
Table 6: Canada pharmaceuticals market share: % share, by value, 2016
Table 7: Canada pharmaceuticals market value forecast: $ billion, 2016–21
Table 8: Canada size of population (million), 2012–16
Table 9: Canada gdp (constant 2005 prices, $ billion), 2012–16
Table 10: Canada gdp (current prices, $ billion), 2012–16
Table 11: Canada inflation, 2012–16
Table 12: Canada consumer price index (absolute), 2012–16
Table 13: Canada exchange rate, 2012–16
Table 14: France pharmaceuticals market value: $ billion, 2012–16
Table 15: France pharmaceuticals market geography segmentation: $ billion, 2016
Table 16: France pharmaceuticals market share: % share, by value, 2016
Table 17: France pharmaceuticals market value forecast: $ billion, 2016–21
Table 18: France size of population (million), 2012–16
Table 19: France gdp (constant 2005 prices, $ billion), 2012–16
Table 20: France gdp (current prices, $ billion), 2012–16
Table 21: France inflation, 2012–16
Table 22: France consumer price index (absolute), 2012–16
Table 23: France exchange rate, 2012–16
Table 24: Germany pharmaceuticals market value: $ billion, 2012–16
Table 25: Germany pharmaceuticals market geography segmentation: $ billion, 2016
Table 26: Germany pharmaceuticals market share: % share, by value, 2016
Table 27: Germany pharmaceuticals market value forecast: $ billion, 2016–21
Table 28: Germany size of population (million), 2012–16
Table 29: Germany gdp (constant 2005 prices, $ billion), 2012–16
Table 30: Germany gdp (current prices, $ billion), 2012–16
Table 31: Germany inflation, 2012–16
Table 32: Germany consumer price index (absolute), 2012–16
Table 33: Germany exchange rate, 2012–16
Table 34: Italy pharmaceuticals market value: $ billion, 2012–16
Table 35: Italy pharmaceuticals market geography segmentation: $ billion, 2016
Table 36: Italy pharmaceuticals market share: % share, by value, 2016
Table 37: Italy pharmaceuticals market value forecast: $ billion, 2016–21
Table 38: Italy size of population (million), 2012–16
Table 39: Italy gdp (constant 2005 prices, $ billion), 2012–16
Table 40: Italy gdp (current prices, $ billion), 2012–16
Table 41: Italy inflation, 2012–16
Table 42: Italy consumer price index (absolute), 2012–16
Table 43: Italy exchange rate, 2012–16
Table 44: Japan pharmaceuticals market value: $ billion, 2012–16
Table 45: Japan pharmaceuticals market geography segmentation: $ billion, 2016
Table 46: Japan pharmaceuticals market share: % share, by value, 2016
Table 47: Japan pharmaceuticals market value forecast: $ billion, 2016–21
Table 48: Japan size of population (million), 2012–16
Table 49: Japan gdp (constant 2005 prices, $ billion), 2012–16
Table 50: Japan gdp (current prices, $ billion), 2012–16
Table 51: Japan inflation, 2012–16
Table 52: Japan consumer price index (absolute), 2012–16
Table 53: Japan exchange rate, 2012–16
Table 54: Russia pharmaceuticals market value: $ billion, 2012–16
Table 55: Russia pharmaceuticals market geography segmentation: $ billion, 2016
Table 56: Russia pharmaceuticals market share: % share, by value, 2016
Table 57: Russia pharmaceuticals market value forecast: $ billion, 2016–21
Table 58: Russia size of population (million), 2012–16
Table 59: Russia gdp (constant 2005 prices, $ billion), 2012–16
Table 60: Russia gdp (current prices, $ billion), 2012–16
Table 61: Russia inflation, 2012–16
Table 62: Russia consumer price index (absolute), 2012–16
Table 63: Russia exchange rate, 2012–16
Table 64: United Kingdom pharmaceuticals market value: $ billion, 2012–16
Table 65: United Kingdom pharmaceuticals market geography segmentation: $ billion, 2016
Table 66: United Kingdom pharmaceuticals market share: % share, by value, 2016
Table 67: United Kingdom pharmaceuticals market value forecast: $ billion, 2016–21
Table 68: United Kingdom size of population (million), 2012–16
Table 69: United Kingdom gdp (constant 2005 prices, $ billion), 2012–16
Table 70: United Kingdom gdp (current prices, $ billion), 2012–16
Table 71: United Kingdom inflation, 2012–16
Table 72: United Kingdom consumer price index (absolute), 2012–16
Table 73: United Kingdom exchange rate, 2012–16
Table 74: United States pharmaceuticals market value: $ billion, 2012–16
Table 75: United States pharmaceuticals market geography segmentation: $ billion, 2016
Table 76: United States pharmaceuticals market share: % share, by value, 2016
Table 77: United States pharmaceuticals market value forecast: $ billion, 2016–21
Table 78: United States size of population (million), 2012–16
Table 79: United States gdp (constant 2005 prices, $ billion), 2012–16
Table 80: United States gdp (current prices, $ billion), 2012–16
Table 81: United States inflation, 2012–16
Table 82: United States consumer price index (absolute), 2012–16
Table 83: United States exchange rate, 2012–15
Table 84: Apotex, Inc.: key facts
Table 85: Merck & Co., Inc.: key facts
Table 86: Merck & Co., Inc.: key financials ($)
Table 87: Merck & Co., Inc.: key financial ratios
Table 88: Pfizer Inc.: key facts
Table 89: Pfizer Inc.: key financials ($)
Table 90: Pfizer Inc.: key financial ratios
Table 91: AstraZeneca PLC: key facts
Table 92: AstraZeneca PLC: key financials ($)
Table 93: AstraZeneca PLC: key financial ratios
Table 94: Laboratoires Pierre Fabre SA: key facts
Table 95: Sanofi SA: key facts
Table 96: Sanofi SA: key financials ($)
Table 97: Sanofi SA: key financials (€)
Table 98: Sanofi SA: key financial ratios
Table 99: Les Laboratoires Servier: key facts
Table 100: Bayer AG: key facts
Table 101: Bayer AG: key financials ($)
Table 102: Bayer AG: key financials (€)
Table 103: Bayer AG: key financial ratios
Table 104: Boehringer Ingelheim GmbH: key facts
Table 105: Boehringer Ingelheim GmbH: key financials ($)
Table 106: Boehringer Ingelheim GmbH: key financials (€)
Table 107: Boehringer Ingelheim GmbH: key financial ratios
Table 108: Novartis AG: key facts
Table 109: Novartis AG: key financials ($)
Table 110: Novartis AG: key financial ratios
Table 111: F. Hoffmann-La Roche Ltd: key facts
Table 112: F. Hoffmann-La Roche Ltd: key financials ($)
Table 113: F. Hoffmann-La Roche Ltd: key financials (CHF)
Table 114: F. Hoffmann-La Roche Ltd: key financial ratios
Table 115: Chiesi Farmaceutici S.p.A.: key facts
Table 116: The Menarini Group: key facts
Table 117: Recordati S.p.A.: key facts
Table 118: Astellas Pharma Inc.: key facts
Table 119: Astellas Pharma Inc.: key financials ($)
Table 120: Astellas Pharma Inc.: key financials (¥)
Table 121: Astellas Pharma Inc.: key financial ratios
Table 122: Daiichi Sankyo Co., Ltd.: key facts
Table 123: Daiichi Sankyo Co., Ltd.: key financials ($)
Table 124: Daiichi Sankyo Co., Ltd.: key financials (¥)
Table 125: Daiichi Sankyo Co., Ltd.: key financial ratios
Table 126: Mitsubishi Tanabe Pharma Corporation: key facts
Table 127: Mitsubishi Tanabe Pharma Corporation: key financials ($)
Table 128: Mitsubishi Tanabe Pharma Corporation: key financials (¥)
Table 129: Mitsubishi Tanabe Pharma Corporation: key financial ratios
Table 130: Takeda Pharmaceutical Company Limited: key facts
Table 131: Takeda Pharmaceutical Company Limited: key financials ($)
Table 132: Takeda Pharmaceutical Company Limited: key financials (¥)
Table 133: Takeda Pharmaceutical Company Limited: key financial ratios
Table 134: GlaxoSmithKline Plc: key facts
Table 135: GlaxoSmithKline Plc: key financials ($)
Table 136: GlaxoSmithKline Plc: key financials (£)
Table 137: GlaxoSmithKline Plc: key financial ratios
Table 138: Johnson & Johnson: key facts
Table 139: Johnson & Johnson: key financials ($)
Table 140: Johnson & Johnson: key financial ratios

LIST OF FIGURES

Figure 1: G8 pharmaceuticals industry, revenue($bn), 2012-21
Figure 2: G8 Pharmaceuticals industry, revenue by country (%), 2016
Figure 3: G8 pharmaceuticals industry, revenue by country ($bn), 2012-16
Figure 4: G8 pharmaceuticals industry forecast, revenue by country ($bn), 2016-21
Figure 5: Canada pharmaceuticals market value: $ billion, 2012–16
Figure 6: Canada pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 7: Canada pharmaceuticals market share: % share, by value, 2016
Figure 8: Canada pharmaceuticals market value forecast: $ billion, 2016–21
Figure 9: Forces driving competition in the pharmaceuticals market in Canada, 2016
Figure 10: Drivers of buyer power in the pharmaceuticals market in Canada, 2016
Figure 11: Drivers of supplier power in the pharmaceuticals market in Canada, 2016
Figure 12: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2016
Figure 13: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2016
Figure 14: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2016
Figure 15: France pharmaceuticals market value: $ billion, 2012–16
Figure 16: France pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 17: France pharmaceuticals market share: % share, by value, 2016
Figure 18: France pharmaceuticals market value forecast: $ billion, 2016–21
Figure 19: Forces driving competition in the pharmaceuticals market in France, 2016
Figure 20: Drivers of buyer power in the pharmaceuticals market in France, 2016
Figure 21: Drivers of supplier power in the pharmaceuticals market in France, 2016
Figure 22: Factors influencing the likelihood of new entrants in the pharmaceuticals market in France, 2016
Figure 23: Factors influencing the threat of substitutes in the pharmaceuticals market in France, 2016
Figure 24: Drivers of degree of rivalry in the pharmaceuticals market in France, 2016
Figure 25: Germany pharmaceuticals market value: $ billion, 2012–16
Figure 26: Germany pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 27: Germany pharmaceuticals market share: % share, by value, 2016
Figure 28: Germany pharmaceuticals market value forecast: $ billion, 2016–21
Figure 29: Forces driving competition in the pharmaceuticals market in Germany, 2016
Figure 30: Drivers of buyer power in the pharmaceuticals market in Germany, 2016
Figure 31: Drivers of supplier power in the pharmaceuticals market in Germany, 2016
Figure 32: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Germany, 2016
Figure 33: Factors influencing the threat of substitutes in the pharmaceuticals market in Germany, 2016
Figure 34: Drivers of degree of rivalry in the pharmaceuticals market in Germany, 2016
Figure 35: Italy pharmaceuticals market value: $ billion, 2012–16
Figure 36: Italy pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 37: Italy pharmaceuticals market share: % share, by value, 2016
Figure 38: Italy pharmaceuticals market value forecast: $ billion, 2016–21
Figure 39: Forces driving competition in the pharmaceuticals market in Italy, 2016
Figure 40: Drivers of buyer power in the pharmaceuticals market in Italy, 2016
Figure 41: Drivers of supplier power in the pharmaceuticals market in Italy, 2016
Figure 42: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Italy, 2016
Figure 43: Factors influencing the threat of substitutes in the pharmaceuticals market in Italy, 2016
Figure 44: Drivers of degree of rivalry in the pharmaceuticals market in Italy, 2016
Figure 45: Japan pharmaceuticals market value: $ billion, 2012–16
Figure 46: Japan pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 47: Japan pharmaceuticals market share: % share, by value, 2016
Figure 48: Japan pharmaceuticals market value forecast: $ billion, 2016–21
Figure 49: Forces driving competition in the pharmaceuticals market in Japan, 2016
Figure 50: Drivers of buyer power in the pharmaceuticals market in Japan, 2016
Figure 51: Drivers of supplier power in the pharmaceuticals market in Japan, 2016
Figure 52: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Japan, 2016
Figure 53: Factors influencing the threat of substitutes in the pharmaceuticals market in Japan, 2016
Figure 54: Drivers of degree of rivalry in the pharmaceuticals market in Japan, 2016
Figure 55: Russia pharmaceuticals market value: $ billion, 2012–16
Figure 56: Russia pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 57: Russia pharmaceuticals market share: % share, by value, 2016
Figure 58: Russia pharmaceuticals market value forecast: $ billion, 2016–21
Figure 59: Forces driving competition in the pharmaceuticals market in Russia, 2016
Figure 60: Drivers of buyer power in the pharmaceuticals market in Russia, 2016
Figure 61: Drivers of supplier power in the pharmaceuticals market in Russia, 2016
Figure 62: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Russia, 2016
Figure 63: Factors influencing the threat of substitutes in the pharmaceuticals market in Russia, 2016
Figure 64: Drivers of degree of rivalry in the pharmaceuticals market in Russia, 2016
Figure 65: United Kingdom pharmaceuticals market value: $ billion, 2012–16
Figure 66: United Kingdom pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 67: United Kingdom pharmaceuticals market share: % share, by value, 2016
Figure 68: United Kingdom pharmaceuticals market value forecast: $ billion, 2016–21
Figure 69: Forces driving competition in the pharmaceuticals market in the United Kingdom, 2016
Figure 70: Drivers of buyer power in the pharmaceuticals market in the United Kingdom, 2016
Figure 71: Drivers of supplier power in the pharmaceuticals market in the United Kingdom, 2016
Figure 72: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United Kingdom, 2016
Figure 73: Factors influencing the threat of substitutes in the pharmaceuticals market in the United Kingdom, 2016
Figure 74: Drivers of degree of rivalry in the pharmaceuticals market in the United Kingdom, 2016
Figure 75: United States pharmaceuticals market value: $ billion, 2012–16
Figure 76: United States pharmaceuticals market geography segmentation: % share, by value, 2016
Figure 77: United States pharmaceuticals market share: % share, by value, 2016
Figure 78: United States pharmaceuticals market value forecast: $ billion, 2016–21
Figure 79: Forces driving competition in the pharmaceuticals market in the United States, 2016
Figure 80: Drivers of buyer power in the pharmaceuticals market in the United States, 2016
Figure 81: Drivers of supplier power in the pharmaceuticals market in the United States, 2016
Figure 82: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2016
Figure 83: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2016
Figure 84: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2016
Figure 85: Merck & Co., Inc.: revenues & profitability
Figure 86: Merck & Co., Inc.: assets & liabilities
Figure 87: Pfizer Inc.: revenues & profitability
Figure 88: Pfizer Inc.: assets & liabilities
Figure 89: AstraZeneca PLC: revenues & profitability
Figure 90: AstraZeneca PLC: assets & liabilities
Figure 91: Sanofi SA: revenues & profitability
Figure 92: Sanofi SA: assets & liabilities
Figure 93: Bayer AG: revenues & profitability
Figure 94: Bayer AG: assets & liabilities
Figure 95: Boehringer Ingelheim GmbH: revenues & profitability
Figure 96: Boehringer Ingelheim GmbH: assets & liabilities
Figure 97: Novartis AG: revenues & profitability
Figure 98: Novartis AG: assets & liabilities
Figure 99: F. Hoffmann-La Roche Ltd: revenues & profitability
Figure 100: F. Hoffmann-La Roche Ltd: assets & liabilities
Figure 101: Astellas Pharma Inc.: revenues & profitability
Figure 102: Astellas Pharma Inc.: assets & liabilities
Figure 103: Daiichi Sankyo Co., Ltd.: revenues & profitability
Figure 104: Daiichi Sankyo Co., Ltd.: assets & liabilities
Figure 105: Mitsubishi Tanabe Pharma Corporation: revenues & profitability
Figure 106: Mitsubishi Tanabe Pharma Corporation: assets & liabilities
Figure 107: Takeda Pharmaceutical Company Limited: revenues & profitability
Figure 108: Takeda Pharmaceutical Company Limited: assets & liabilities
Figure 109: GlaxoSmithKline Plc: revenues & profitability
Figure 110: GlaxoSmithKline Plc: assets & liabilities
Figure 111: Johnson & Johnson: revenues & profitability
Figure 112: Johnson & Johnson: assets & liabilities
Skip to top


Ask Your Question

Pharmaceuticals Global Group of Eight (G8) Industry Guide 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: